Target intelligence / Profile preview

Bcl-2-like protein 10 (BCL2L10) (BCL-b)

Target
BCL-b
Molecular classification
Other
01

Overview

Bcl-2-like protein 10 (BCL2L10), commonly known as Bcl-B, is an anti-apoptotic member of the B-cell lymphoma 2 (Bcl-2) family of proteins. It contains all four Bcl-2 homology (BH) domains (BH1, BH2, BH3, and BH4) and a C-terminal transmembrane domain that anchors it to the outer mitochondrial membrane and endoplasmic reticulum. Bcl-B promotes cell survival by binding to and neutralizing pro-apoptotic proteins such as Bax, Bim, and Bok, thereby preventing mitochondrial outer membrane permeabilization (MOMP) and subsequent caspase activation. In addition to its role in apoptosis, Bcl-B regulates autophagy by interacting with Beclin 1 and modulates calcium homeostasis at the endoplasmic reticulum.\n\nIn pathological contexts, Bcl-B is overexpressed in various malignancies, including lung adenocarcinoma, melanoma, and breast cancer, where its elevated levels correlate with poor prognosis and resistance to chemotherapeutic agents and other BH3 mimetics. Conversely, in some cancers, it may act as a tumor suppressor, highlighting its complex, context-dependent role. Pharmacological targeting of Bcl-B is an active area of oncology research. While broad-spectrum BH3 mimetics like gossypol and gambogic acid inhibit Bcl-B alongside other family members, selective small-molecule inhibitors such as ML258 have been developed to specifically disrupt Bcl-B interactions, offering a potential strategy to sensitize cancer cells to chemotherapy while minimizing the systemic toxicities associated with pan-Bcl-2 inhibition.

Other names
Bcl-BBcl2-L-10NrhBooDivaApoptosis regulator Bcl-BB-cell lymphoma 2 family protein resembling BooBCLBBCL2L10
02

Mechanism of action

Antagonism of anti-apoptotic activity via BH3-mimetic binding, which disrupts the interaction of Bcl-B with pro-apoptotic proteins such as Bax, Bim, and Bok, thereby restoring the intrinsic apoptotic pathway and promoting cell death.

03

Biological functions

ApoptosisCell deathAutophagyCell cycle
04

Disease associations

CancerOther
05

Safety considerations

Potential for off-target toxicity with non-selective pan-Bcl-2 inhibitorsRisk of thrombocytopeniaPotential impact on oogenesis and embryonic developmentRisk of keratinocyte apoptosis and associated skin toxicities such as toxic epidermal necrolysis
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

BCL2L10 expression levelBcl-B protein levelUbiquilin-1 expression levelBok expression level

Beyond the preview

Go deeper on Bcl-2-like protein 10 (BCL2L10) (BCL-b).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bcl-2-like protein 10 (BCL2L10) (BCL-b).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call